高血壓是持續(xù)血壓過高的疾病，會(huì)引起 中風(fēng)、心臟病、血管瘤、腎衰竭等疾病，高血壓是一種以動(dòng)脈壓升高為特征，可伴有心臟、血管、腦和腎臟等器官功能性或器質(zhì)性改變的全身性疾病。DHET、HETE類代謝物可作為檢測高血壓疾病的代表標(biāo)志物，發(fā)揮著重要的作用。  

12-HETE，ELISA的特異性是用真實(shí)的12-HETE和脂肪酸進(jìn)行研究的，根據(jù)其結(jié)構(gòu)，這些脂肪酸可能與12-HETE競爭結(jié)合對(duì)抗12-HETE的抗體。Anti-12 -HETE僅與15-HETE和13-HODE發(fā)生輕微交叉反應(yīng)。這種代謝物在人類高血壓中的作用非常之高。  

14,15- DHET是可溶性環(huán)氧化物水解酶（sEH）介導(dǎo)的EETs代謝的代表性代謝物，由細(xì)胞色素P450 (CYPs) 2C和2J的花生四烯酸環(huán)氧合酶活性產(chǎn)生。使用14,15- DHET ELISA，發(fā)現(xiàn)14,15- DHET水平與高血壓、腦損傷和中風(fēng)呈正相關(guān)，EET水平與癌細(xì)胞轉(zhuǎn)移表型和胰島素抵抗呈正相關(guān)。   

高血壓是由于花生四烯酸（AA）ω-羥化酶（20-HETE合成）活性的細(xì)胞色素P450s CYP4A, CYP4F和CYP1B1的增加而確定的。因此，20-HETE已成為高血壓和中風(fēng)的生物標(biāo)志物和治療靶點(diǎn)。該ELISA試劑盒適用于最多24個(gè)生物樣本（三份）中20-HETE的測定。  

【 爆款 高血壓相關(guān)產(chǎn)品】

【引文賞析】

【DRD-DH1】

Luo, J, Yao, J-F, Deng, X-F, Zheng, X-D, Jia, M, Wang, Y-Q, Huang, y and Zhu, J-H. 14,15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin avB3 and activating FAK/PI3K/AKT signaling. J. Exp Clin. Cancer Res. 37:23. 2018.   

Akasaka T, Sueta D, Arima Y, Tabata N, Takasio S, Izumiya Y, Yamamoto E, Tsujita K, Kojima S, Kaikita K, Kajiwara A, Morita K, Oniki K, Saruwatari J, Nakagawa K, Hokimoto S. CYP2C19 variants and epoxy eicosatrienoic acids in patients with microvascular angina. IJC Heart & Vasculature 15: 15-20 (2017).  

【DRD-DH2】

Liu P, Zhang S, Gao J, Lin Y, Shi G, He W, Touyz RM, Yan L, Huang H. Downregulated serum 14,15- Epoxyeicosatrienoic acid is associated with abdominal aortic calcification in patients with primary aldosteronism. Hypertension 71: 592-598, 2018.  

Akasaka T, Sueta D, Arima Y, Tabata N, Takasio S, Izumiya Y, Yamamoto E, Tsujita K, Kojima S, Kaikita K, Kajiwara A, Morita K, Oniki K, Saruwatari J, Nakagawa K, Hokimoto S. CYP2C19 variants and epoxy eicosatrienoic acids in patients with microvascular angina. IJC Heart & Vasculature 15: 15-20 (2017).  

【DRD-12H1】

González-Nú?ez, Daniel, Joan Claria, Francisca Rivera, Esteban Poch. Increased levels of 12(S)-HETE in patients with essential hypertension. Hypertension 2001; 37: 334-338.   

Szczeklik W, Sanak M, Mastalerz L, Soko?owska BM, Gielicz A, Soja J, Kumik J, Musia? J, Szczeklik A.12-hydroxy-eicosatetraenoic acid (12-HETE): a biomarker of Churg-Strauss syndrome. Clin Exp Allergy. 2012 Apr;42(4):513-22.   

【DRD-15H1】

Dobrian AD, Lieb DC, Cole BK, Taylor-Fishwick DA, Chakrabarti SK, Nadler JL. Functional and pathological roles of the 12- and 15-lipoxygenases. Progress in Lipid Research (2011) 50, 115-131 and references therein.   

Pidgeon GP, Lysaght J, Krishnamoorthy S, Reynolds JV, O'Byrne K, Nie D, Honn KV. Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev (2007) 26, 503–524 and references therein.  

【DRD-20H1】

Bou-Fakhredin, R. et al. (2021) CYP450 mediates reactive oxygen species production in a mouse modl of B-thalassemia through an increase in 20-HETE activity. Int. J. Mol. Sci 22:110. PMID:?33498614 CYP4A and CYP4F-induced 20-HETE production mediates reactive oxygen species overgeneration in Hbbth3/+ mice. 

Yu, J. et al. (2021) Cytochrome P450 CYP2E1 suppression ameliorates cerebal ischemia reperfusion injury. Antioxidants 10, 52. PMID:?33466250 20-HETE production increased 41% in CYP2E1 KO mice following ischemia reperfusion injury.  

Detroit R&D完善的庫存及供應(yīng)體系以及穩(wěn)定的純化技術(shù)，保證產(chǎn)品均能現(xiàn)貨供應(yīng)和產(chǎn)品質(zhì)量的穩(wěn)定性。Detroit R&D研發(fā)公司已經(jīng)建立了成功的銷售記錄，通過直接銷售和24個(gè)分銷商向美國和全球研究人員銷售產(chǎn)品。18個(gè)美國國立衛(wèi)生研究院（NIH）SBIR第一階段和第二階段（>1000萬）獎(jiǎng)項(xiàng)，以開發(fā)高血壓診斷，線粒體DNA損傷測定，癌癥微陣列，前列腺癌的糖基化生物標(biāo)志物，糖基化蛋白在乳腺癌和循環(huán)核酸基肺癌中的生物標(biāo)志物和8項(xiàng)已頒發(fā)專利和6項(xiàng)正在申請(qǐng)專利。    

      作為Detroit R&D在中國的區(qū)域代理，艾美捷科技有限公司將為中國客戶提供最全面的Detroit R&D以及客戶訂制化服務(wù)。歡迎大家隨時(shí)聯(lián)系我們。